$3.50
+0.41 (+13.27%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where RXRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
9 interventional · 1 with posted results
Held by 16 tracked-famous managers (BAILLIE GIFFORD & CO, MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MILLENNIUM MANAGEMENT LLC, +11 more) · FINRA short interest 9.3 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 6 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsNCT07517198Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: EXS74539 | Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC) | 40 | Mar 2029 | ≤ 954 d | 2026-06-10 |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic CancerNCT06678659Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REC-1245 | Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas | 170 | 2028-10-30 | in 802 d | 2026-05-08 |
| Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesNCT06980116Number of Participants with Treatment-emergent Adverse Events (TEAEs)Open-label · Treatment | Phase 1 | Recruiting | Drug: EXS73565 | Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Diffuse-large B-cell Lymphoma (DLBCL), Waldenstrom's Macroglobulinemia (WM) | 85 | Jun 2028 | ≤ 680 d | 2026-08-13 |
| Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsNCT05985655Number of Participants With Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: GTAEXS617, SoC | Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC) | 230 | Jan 2028 | ≤ 529 d | 2026-08-13 |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)NCT05552755Part 1: Maximum (Peak) Plasma Drug Concentration (Cmax) of REC-4881Non-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: REC-4881, Placebo | Familial Adenomatous Polyposis | 67 | Jun 2027 | ≤ 314 d | 2026-06-05 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated MeningiomasNCT05130866Cohort A: Number of Participants with Progression-free survival (PFS) at 6 MonthsRandomized · Double-masked · Treatment | Phase 2/3 | Terminatedsponsor's stated reason: Study was terminated due to sponsor decision. This decision was not related to safety concerns with REC-2282. | Drug: REC-2282, Placebo | Neurofibromatosis Type 2 | 25 | 2025-08-18actual | — | 2026-08-17 |
| The Symptomatic Cerebral Cavernous Malformation Trial of REC-994NCT05085561Incidence and severity of adverse events (AEs)Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: REC-994, Placebo | Cerebral Cavernous Malformation | 62 | 2025-06-30actual | — | 2026-06-23 |
| The Clostridioides Difficile Trial of REC-3964NCT06536465results2025-11-17Number of Participants With Survival Without Recurrence or Requirement for Additional Clostridioides Difficile Infection (CDI) TreatmentRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to sponsor decision. This decision was not related to safety concerns. | Drug: REC-3964 | Recurrent Clostridioides Difficile Infection | 3 | 2025-05-06actual | — | 2025-11-17 |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC MutationNCT06005974Number of Participants with Dose Limiting ToxicitiesNon-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study was terminated due to sponsor decision. This decision was not related to safety concerns. | Drug: REC-4881 | AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor | 18 | 2025-02-24actual | — | 2026-02-23 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19